Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma

Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma

(2020) Shelly Kalaora et al.   Nature Communications

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

(2019) Michael Friedrich et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy

(2019) Jeffrey C. Thompson et al.   LUNG CANCER

Defective HLA class I antigen processing machinery in cancer

(2018) Lei Cai et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

(2018) Daniela S. Thommen et al.   NATURE MEDICINE

MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy

(2018) Irene Romero et al.   Frontiers in Immunology

Biological Consequences of Major Histocompatibility Class-II Expression by Tumor Cells in Cancer

(2018) Margaret L Axelrod et al.   CLINICAL CANCER RESEARCH

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

(2018) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape

(2017) Francisco Perea et al.   Oncotarget

Rejection versus escape: the tumor MHC dilemma

(2016) Federico Garrido et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

(2016) Carolina Pereira et al.   CLINICAL CANCER RESEARCH

The urgent need to recover MHC class I in cancers for effective immunotherapy

(2016) Federico Garrido et al.   CURRENT OPINION IN IMMUNOLOGY

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

(2016) Joshua D Campbell et al.   NATURE GENETICS

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells

(2016) Sofia R. Gameiro et al.   Oncotarget

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells

(2016) E. J. Brea et al.   Cancer Immunology Research

Comprehensive evaluation of AmpliSeq transcriptome, a novel targeted whole transcriptome RNA sequencing methodology for global gene expression analysis

(2015) Wenli Li et al.   BMC GENOMICS

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

(2015) Sachet A Shukla et al.   NATURE BIOTECHNOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cell Surface Expression Level Variation between Two Common Human Leukocyte Antigen Alleles, HLA-A2 and HLA-B8, Is Dependent on the Structure of the C Terminal Part of the Alpha 2 and the Alpha 3 Domains

(2015) Christoffer Dellgren et al.   PLoS One

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells

(2013) P. Leone et al.   JNCI-Journal of the National Cancer Institute

Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells

(2011) T. Imai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

“Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy

(2010) Federico Garrido et al.   INTERNATIONAL JOURNAL OF CANCER

NLR family member NLRC5 is a transcriptional regulator of MHC class I genes

(2010) T. B. Meissner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas

(2009) Helen P. Cathro et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Different regulation of MHC Class I antigen processing components in human tumors

(2009) Barbara Seliger   Journal of Immunotoxicology